Welcome to our dedicated page for Cannabis Bioscience International Holdings SEC filings (Ticker: CBIH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cannabis Bioscience International Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cannabis Bioscience International Holdings's regulatory disclosures and financial reporting.
Cannabis Bioscience International Holdings, Inc. reported another quarterly loss and flagged substantial doubt about its ability to continue as a going concern for the period ended February 28, 2026.
Revenue for the nine months was $88,671, sharply lower than $268,066 a year earlier, mainly from reduced clinical trial contracts. Operating expenses were $330,903, leading to a nine-month net loss of $303,546.
The balance sheet is highly strained: cash was only $90, total liabilities were $1,468,674, and stockholders’ deficiency was $1,467,130. Working capital was negative $1,217,630, and accumulated deficit reached $6,186,448. The company relies on high-interest debt, related-party financing and has several loans in arrears or default while still having over 11.6 billion common shares outstanding and no proceeds yet from its previously declared effective equity offering.
Cannabis Bioscience International Holdings, Inc. filed a Form 12b-25 notifying the SEC that its Quarterly Report on Form 10-Q for the quarter ended February 28, 2026 could not be filed on time. The company cites that the financial information for the quarter "cannot be analyzed and completed on a timely basis." The company estimates a loss from operations of approximately $82,000 for the three months ended February 28, 2026, versus a loss of $129,234 for the three months ended February 29, 2025. For the nine months ended February 28, 2026, it estimates a loss from operations of approximately $252,000 versus $286,465 for the prior-year nine-month period. Estimated three-month revenues are approximately $11,000 with gross profit of $8,000; nine-month revenues are approximately $89,000 with gross profit of $67,000. The filing lists changes in operating expense categories, including decreases in general and administrative costs and contract labor, and increases in professional fees, rent and officer compensation.
Cannabis Bioscience International Holdings, Inc. reported another weak quarter, with revenues for the three months ended November 30, 2025 falling to $53,266 from $74,248 a year earlier, mainly from lower clinical trial activity.
Operating expenses rose to $138,643, driven largely by higher professional fees, pushing the quarterly net loss to $116,966 versus a loss of $79,528 in the prior-year quarter. For the six-month period, revenue dropped sharply to $77,466 from $253,135, while the net loss widened to $199,612.
The balance sheet remains strained: cash was only $132, total assets were $22,131, and there was a working capital deficit of $1,113,695 and stockholders’ deficiency of $1,363,195 as of November 30, 2025. Management discloses substantial doubt about the company’s ability to continue as a going concern, and it is relying on related-party and SBA debt while seeking additional financing. On December 31, 2025, the company also terminated its Pharmacology University education business.
Cannabis Bioscience International Holdings, Inc. filed a notification that it will be late filing its Quarterly Report on Form 10-Q for the quarter ended November 30, 2025, stating that the financial information cannot be analyzed and completed on a timely basis.
The company estimates a loss from operations of approximately $96,000 for the three months ended November 30, 2025, compared with $59,627 for the same period in 2024. Estimated revenues are about $53,000 and gross profit about $43,000, versus $74,248 and $66,445, respectively, a year earlier. Total operating expenses are expected to be around $139,000, compared with $126,072, driven by higher general and administrative expenses and professional fees, partly offset by lower contract labor and rent.
Net loss for the quarter is expected to be approximately $109,000, compared with $79,528 in the prior-year period. The company notes these results are preliminary, subject to further review by management and its independent registered public accounting firm, and may differ substantially from the final figures reported in the Form 10-Q.
Cannabis Bioscience International Holdings (CBIH) reported Q1 results for the quarter ended August 31, 2025. Revenue fell to $24,200 from $178,887 a year ago, driven mainly by fewer clinical trial contracts. Gross profit was $16,057, with operating expenses of $90,841, leading to an operating loss of $74,784. After other items, including a $29,322 gain from the change in derivative liabilities and $17,368 of interest expense, net loss was $82,645 (vs. $76,305 last year).
Liquidity remains tight. Cash was $223 at quarter-end, and the company disclosed a working capital deficit of $996,728 and a stockholders’ deficiency of $(1,246,228), with total liabilities of $1,265,170. Management states there is substantial doubt about the company’s ability to continue as a going concern. Two customers represented 95% of quarterly revenue. The company noted no sales under its effective S-1 to date. Shares outstanding were 11,626,749,347 as of October 22, 2025.
Cannabis Bioscience International Holdings (CBIH) filed a Notification of Late Filing (Form 12b-25) for its Form 10-Q for the period ended August 31, 2025, citing that the financial information for the quarter could not be analyzed and completed on a timely basis.
The company provided preliminary estimates indicating a smaller loss from operations of approximately $66,000 versus $97,604 a year earlier. Estimated revenue is about $36,000 compared with $178,887, and estimated gross profit is about $28,000 versus $170,525 for the prior-year quarter. Estimated total operating expenses are approximately $94,000, down from $268,129, reflecting substantial decreases in general and administrative expenses, professional fees, share-based compensation, and rent. Estimated net loss is about $42,511, compared with $76,305 in the prior year.
Cannabis Bioscience International Holdings, Inc. (CBIH) reported operations across three segments: clinical research (Alpha Research Institute), education and publishing (Pharmacology University) and planned CBD product sales (VitaCookies). For the year ended May 31, 2025, the company recorded revenues of $262,916 and cost of revenues of $203,242, producing operating loss of $421,365 and a reported net loss of $548,820. The company used $329,627 in operating cash flows, had a working capital deficit of $916,878, and an accumulated deficit of $5,882,901. It disclosed concentration risk with 91% of gross revenue from a small number of customers in 2025.
The company disclosed multiple debt arrangements, several in default or arrears, EIDL loans outstanding (~$249,500 noncurrent portion), related-party financing (Jones Note ~$340,855), and convertible-note features on some financings. Management highlighted going concern indicators and weaknesses in controls and board oversight, including no independent directors or audit committee. The filing lists numerous patent applications and product concepts, plus equity issuances raising $244,250 in 2025 from private stock sales.
Cannabis Bioscience International Holdings, Inc. (CBIH) reported operations across three segments: clinical research (Alpha Research Institute), education and publishing (Pharmacology University) and planned CBD product sales (VitaCookies). For the year ended May 31, 2025, the company recorded revenues of $262,916 and cost of revenues of $203,242, producing operating loss of $421,365 and a reported net loss of $548,820. The company used $329,627 in operating cash flows, had a working capital deficit of $916,878, and an accumulated deficit of $5,882,901. It disclosed concentration risk with 91% of gross revenue from a small number of customers in 2025.
The company disclosed multiple debt arrangements, several in default or arrears, EIDL loans outstanding (~$249,500 noncurrent portion), related-party financing (Jones Note ~$340,855), and convertible-note features on some financings. Management highlighted going concern indicators and weaknesses in controls and board oversight, including no independent directors or audit committee. The filing lists numerous patent applications and product concepts, plus equity issuances raising $244,250 in 2025 from private stock sales.